Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy

Urologia Internationalis

Volumn 77, Issue 1, 2006, Pages 69-75

  Liu, I Jenna ^a   Lai, Yen Man ^a   Espiritu, Jocelyn I ^a   Segall, George M ^a   Srinivas, Sandy ^a   Nino Murcia, Matilde ^a   Terris, Martha K ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Bladder cancer; Imaging; Positron emission tomography; Staging; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METABOLIC RATE; METABOLISM; METASTASIS; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; URINARY BLADDER NEOPLASMS;

EID: 33745823539     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092937     Document Type: Article

References (28)

1. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J, Phelps ME: PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106.
2. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL: Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:746-749.
3. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, Fleshman JW, Read TE, Philpott GW, Kodner IJ: Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-620.
4. Graeber GM, Gupta NC, Murray GF: Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:719-727.
5. Hoh CK, Seltzer MA, Franklin F, DeKernion JB, Phelps ME, Belldegrun A: Positron emission tomography in urological oncology. J Urol 1998;159:347-356.
6. Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE: Positron emission tomography: introduction of a new procedure in diagnosis of urologie tumors and initial clinical results. Urologe A 1995;34:138-142.
7. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS: Positron emission tomography in urologic oncology. Cancer Control 2002;9:335-342.
8. Hofer C, Kubler H, Hartung R, Breul J, Avril N: Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 2001;40:481-487.
9. Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, Grossman HB: Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol 1991;145:279-283.
10. Kosuda S, Kison P, Greenough R, Grossman B, Wahl R: Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997;24:615-620.
11. Heicappell R, Muller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Muller-Gartner H, Ackermann R: Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 1-[(18)F]-2-deoxy-D- glucose. Eur Urol 1999;36:582-587.
12. Letocha H, Ahlstrom H, Malmstrom PU, Westlin JE, Fasth KJ, Nilsson S: Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Urol 1994;74:767-774.
13. Liu IJ, Segall GM, Nino-Murcia M, Terris MK: Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of transitional cell carcinoma. Adv Exp Med Biol 2003;539:129-142.
14. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388.
15. Sobel BE: Positron tomography and myocardial metabolism: an overview. Circulation 1985;72:22-30.
16. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV: Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988;150:189-197.
17. Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, VanderLaak JA, Kondacki H, Ruijs SH: Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998;207:791-797.
18. Okada J, Oonishi H, Yoshikawa K, Imaseki K, Uno K, Itami J, Arimizu N: FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med 1994;8:109-113.
19. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WK, Moser RP Jr, et al: Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992;12:269-279.
20. Shreve PD, Anzai Y, Wahl RL: Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77.
21. Bhargava P, Zhuang H, Kumar R, Charron M, Alavi A: Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med 2004;29:429-439.
22. Okazumi S, Enomoto K, Fukunaga T, et al: Evaluation of the cases of benign disease with high accumulation on the examination of 18F- flourodeoxyglucose PET. Kaku Igaku 1993;30:1439-1443.
23. Swetter S, Carroll L, Johnson D, Segall G: Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002;9:646-653.
24. Fujii H, Enomoto K, Ikeda T, Hojo T, Yasuda S, Ide M, Shohtsu A, Kameyama K, Kubo A: Lymph node metastasis from breast cancer diagnosed by F-18 FDG whole-body PET. Breast Cancer 2000;7:165-168.
25. Bakheet SM, Powe J, Ezzat A, Rostom A: F-18-FDG uptake in tuberculosis. Clin Nucl Med 1998;23:739-742.
26. Hautzel H, Muller-Gartner HW: Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384-1386.
27. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, Jingu K, Masuda K: Assessment of response to cancer therapy using fluorine-18- fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
28. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD: Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-4661.